Effect of Covishieldtm (AZD1222) Vaccination on Incidences and Severity of Covid-19 among Health-Care Workers
Downloads
Introduction: Limited information is available regarding effect of vaccination on protection against Covid-19 infections and their severity as well. Objectives: In the present study, we assessed the effect of Covid-19 vaccination on incidences and severity of break through Covid-19 infections. Method: This retrospective study was conducted at a tertiary care center in Northern India during one calendar year, 1st August 2021 to 31st July 2022. The study population included Health-care workers (HCWs) who were treated for Covid 19 infection and had already received at least 1 dose of Covishield TM (AZD1222) Covid-19 vaccine. Results: Out of 1868 health care workers enrolled for the study, 513 contracted Covid-19 infections. Amongst infected HCWs, number of single and double doses of CovishieldTM (AZD1222) recipients were 112 and 401 respectively. Out of the 513 covid positive HCWs, 459 (89.4%) had mild disease, whereas 54 (10.6%) had moderate disease. None of the HCWs developed severe disease and no mortality was noted in either group. Conclusion: In this study, we found that immunization with two doses of CovishieldTM (AZD1222) vaccine was associated with decline in number of cases with moderate or severe Covid-19. Moreover, immunization with even single dose of CovishieldTM (AZD1222) vaccine prevented development of severe disease. Henceforth, it is concluded that although, immunization with CovishieldTM (AZD1222) could not protect all recipients from SARS-Cov-2 infection, it did prevent the progress of disease to severe grades.
Abhilash, K. P. P. et al. (2022) ‘Impact of Prior Caccination with CovishieldTM and Covaxin® on Mortality among Symptomatic COVID-19 Patients during the Second Wave of the Pandemic in South India during April and May 2021: A Cohort Study’, Vaccine, 40(13), pp. 2107–2113. doi: 10.1016/j.vaccine.2022.02.023.
Bhadauria DS et al., (2023). Antibody Response to ChAdOx1 nCoV-19 (Covishield®) Vaccine in People on Maintenance Hemodialysis. Seminars in Dialysis. 2023 Nov-Dec;36(6):477-482. DOI: 10.1111/sdi.13149.
Bouton, T. C. et al. (2021) ‘Coronavirus Disease 2019 Vaccine Impact on Rates of Severe Acute Respiratory Syndrome Coronavirus 2 Cases and Postvaccination Strain Sequences Among Health Care Workers at an Urban Academic Medical Center: A Prospective Cohort Study’, Open Forum Infectious Diseases, 8(10), pp. 1–8. doi: 10.1093/ofid/ofab465.
Contractor, A. et al. (2022) ‘Effectiveness of Covid-19 Vaccines Workers in Mumbai, India: A Retrospective Cohort Analysis’, PlosOne, 17(10), pp. 1–12. doi: 10.1371/journal.pone.0276759.
Forni, G. and Mantovani, A. (2021) ‘COVID-19 Vaccines: Where We Stand and Challenges Ahead’, Cell Death & Differentiation, 28, pp. 626–639. doi: 10.1038/s41418-020-00720-9.
Ben Fredj, S. et al. (2022) ‘Risk Factors for Severe Covid-19 Breakthrough Infections: An Observational Longitudinal Study’, BMC Infectious Diseases, 22, pp. 1–11. doi: 10.1186/s12879-022-07859-5.
Gebhard, C. et al. (2020) ‘Impact of Sex and Gender on COVID-19 Outcomes in Europe’, Biologi of Sex Differences, 11, pp. 1–13. doi: doi: 10.1186/s13293-020-00304-9.
Goel, A. et al., (2022). Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield®) in Patients with Liver Cirrhosis. Vaccines 2022, 10, 1837. doi.org/10.3390/ vaccines10111837
Lee, Y. K. et al. (2022) ‘Predictors of COVID-19 Outcomes: Interplay of Frailty, Comorbidity, and Age in COVID-19 Prognosis’, Medicine, 101(51), pp. 1–5. doi: 10.1097/MD.0000000000032343.
Malhotra, V. et al. (2022) ‘A Study to Assess Symptom Profile and Break Through Infections Among Health Care Workers Post Covid Vaccination at Tertiary Care Health Facility’, Indian Journal of Community Medicine, 47(3), pp. 369–374. doi: 10.4103/ijcm.ijcm.
Mohith, S. and Chandrashekhar, H. (2022) ‘Breakthrough Covid 19 Infections after 2 Doses of Covid 19 Vaccination and Comparing Severity between Hospitalized and non Hospitalized in Tertiary Care Hospital’, The Journal of the Association of Physicians of India, 70(4), pp. 11–12.
Sanjeev, O.P. et al. (2022) ‘COVID-19 Vaccine-related Functional Neurological Disorders in the Emergency Department’, Canadian Journal of Emergency Medicine, 24(4), pp.455-456. doi.org/10.1007/s43678-022-00272-6.
Scully, E. P. et al. (2020) ‘Considering How Biological Sex Impacts Immune Responses and COVID-19 Outcomes’, Nature Reviews Immunology, 20(7), pp. 442–447. doi: 10.1038/s41577-020-0348-8.
Thachanun P. et al (2023). The Immunogenicity of the ChAdOx1 nCoV-19 Vaccination in Participants with Underlying Comorbidity Diseases: A Prospective Cohort Study, Human Vaccines & Immunotherapeutics, 19:2, 2251850, DOI: 10.1080/21645515.2023.2251850
Tyagi, K. et al. (2021) ‘Breakthrough COVID19 Infections after Vaccinations in Healthcare and other Workers in A Chronic Care Medical Facility in New Delhi, India’, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(3), pp. 1007–1008. doi: 10.1016/j.dsx.2021.05.001.
Uschner, D. et al. (2022) ‘Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina’, Vaccines, 10(11), pp. 1–10. doi: 10.3390/vaccines10111922.
Verma A. et al., (2022) Durability of ChAdOx1 nCoV-19 (Covishield®) Vaccine Induced Antibody Response in Health Care Workers. Vaccines (Basel). 2022 Dec 30;11(1):84. doi: 10.3390/vaccines11010084.
Victor, P. J. et al. (2021) ‘Protective Effect of COVID-19 Vaccine Among Health Care Workers During the Second Wave of the Pandemic in India’, Mayo Clinic Proceedings, 96(9), pp. 2493–2494. doi: 10.1016/j.mayocp.2021.06.003.
Zakaria, D. et al. (2023) ‘Associations between Chronic Conditions and Death in Hospital among Adults (aged 20+ Years) during First Acute Care Hospitalizations with a Confirmed or Suspected COVID-19 Diagnosis in Canada’, PLoS ONE, 18(1), pp. 1–17. doi: 10.1371/journal.pone.0280050.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
In order to be accepted and published by The Indonesian Journal of Occupational Safety and Health, Author(s) who submit an article should complete all the review process. The copyright of received articles assigned to the The Indonesian Journal of Occupational Safety and Health and Department of Safety and Health, Universitas Airlangga as publishers of the journal. The intended copyright includes the rights to publish articles in various forms (including reprints).
The Editorial Team of The Indonesian Journal Of Occupational Safety and Health and Department of Safety and Health strive to ensure that no errors occur in the articles that have been published, both data errors and statements in the article.
Users of this website will be licensed to use materials from this website following the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. No fees charged. Please use the materials accordingly.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
How to Submit Articles in OJS
